Editas Medicine (EDIT) presented preclinical data and clinical milestones for its lead asset, EDIT-401, at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026.
The company described EDIT-401, a one-time in vivo CRISPR-edited medicine targeting liver-produced proteins, as central to its strategy. CEO Gilmore O'Neill said Editas is "entirely focused on the development of in vivo delivered CRISPR edited medicines" with an aim to create therapies that make a substantial change to the standard of care.
Preclinical studies of EDIT-401 in non-human primates showed mean reductions of approximately 90% in LDL cholesterol, lipoprotein(a), and ApoB. The compound achieved editing of roughly 15% of hepatocyte alleles on a monoallelic basis—about 30% of cells with one allele edited—and produced at least a six-fold increase in LDL receptor expression in liver hepatocytes.
O'Neill pointed to human genetic data from naturally occurring gain-of-function variants in Icelandic and French families, where LDL cholesterol levels ranged from 13 to 60 milligrams per deciliter. Published kindred data showed roughly a three-fold upregulation of LDL receptors. Cardiovascular risk drops about 20% for every 40 mg/dL reduction in LDL over five years, he noted.
The estimated human translation dose is approximately 0.5 to 0.6 mg/kg, derived from a non-human primate dose of 1.5 mg/kg using a crude 3:1 ratio. O'Neill emphasized the platform's versatility: switching liver-targeting to a different gene requires only a 20-nucleotide change in the guide RNA, while the mRNA encoding Cas9 and the lipid nanoparticle remain unchanged.
CFO Amy Parison said Editas ended Q3 2024 with $212 million in cash, providing a runway into the second half of 2028. That position should allow the company to advance EDIT-401 through early clinical stages.
A pre-IND meeting with the FDA and its Center for Biologics Evaluation and Research took place in early 2024. First patient dosing targeted 2024 via Australian Human Research Ethics Committees. Safety data is expected in the first quarter of 2027, with top-line efficacy data anticipated in late 2027 from Phase I Part 1 of the HORIZON trial.
U.S. market entry and clinical trials are targeted for 2027, pending manufacturing documentation.
At the time of the conference, Editas Medicine's stock closed at $3.03, down $0.20 or 6.19%.
Wells Fargo biotech analyst Yanan Zhu covered the presentation.
